KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

Stock Information for PLUS THERAPEUTICS Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PLUS THERAPEUTICS Inc.

KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.